D uring the past 2 decades, the incidence of melanoma has increased more rapidly than that of any other cancer in white skinned populations. [1] [2] [3] In Australia melanoma is the fourth most common invasive cancer with a total of 7891 new cases and 979 deaths in 1998. 4 There were 5659 new cases and 1509 deaths from melanoma in the United Kingdom in 1996 5 and an estimated 51 400 new cases and 7800 deaths in the United States in 2001. 6 Melanoma is an important cause of morbidity and mortality worldwide and in Australia it is one of the most common causes of death from cancer in adults under 40 years.
Survival after treatment for melanoma is strongly inversely related to tumour thickness at diagnosis, 7 suggesting that earlier diagnosis would reduce mortality. Skin screening-that is, careful examination of the skin of asymptomatic people to identify those who may have melanoma-may be one way to achieve this. Screening is currently advocated by various authoritative bodies [8] [9] [10] and the practice of skin screening is increasing, particularly in populations with moderate to high incidence of melanoma such as Australia and the United States. [11] [12] [13] [14] [15] However, unlike other cancers for which population screening is recommended such as breast, 16 17 colorectal, 18 19 and cervical cancer, 20 21 there is no conclusive scientific evidence from randomised trials or cohort studies that screening for melanoma reduces mortality and no direct evidence of its cost effectiveness, hazards, and limitations in practice. 22 A single case-control study of skin self examination 23 showed a reduction in incidence as well as a reduction in mortality after skin self examination, although it is difficult to dismiss recall and selection bias as alternative explanations for this result. 24 Here we describe the design of the first, and currently the only, large randomised controlled trial of a community based screening programme for malignant melanoma, the pilot phase of which is now underway in Queensland.
METHODS

Aims of the randomised trial
The primary aim of the trial is to determine the effectiveness of a community based screening programme in reducing mortality from melanoma. The trial is designed to detect a 20% reduction in mortality from melanoma in the 15 years from the beginning of the intervention period. This would represent a considerable public health benefit, comparable with the reduction in mortality shown by breast and colorectal cancer screening trials. [16] [17] [18] [19] Secondary aims are to document the implementation of the screening programme; to determine its effectiveness in increasing participation in screening and in reducing the incidence of thick melanomas (thicker than 0.75 mm and thicker than 1.5 mm); and to determine the sensitivity, specificity, and costs of screening population for melanoma in the population by primary care physicians.
Design of the randomised trial
This is a cluster randomised controlled trial. The sample comprises 44 eligible Queensland communities (aggregate population of 560 000 adults aged 30 or more) randomised into intervention or control groups (fig 1) to receive, respectively, the community based melanoma screening programme for 3 years or usual medical care. Communities are matched on the basis of broad geographical location, total population, and socioeconomic status as determined from the 1996 Australian census and randomisation is within pairs. Although the rate of uptake of screening and its subsequent decline is unknown, it is likely that increased screening activity will continue in the intervention group beyond the 3 years of the formal programme.
Outcome measures
Clinical outcome measures
The primary outcome measure for the trial is mortality from melanoma among members of the inception cohort, defined as all adults 30 years or older resident in intervention or control communities at the beginning of the intervention period and registered on the Queensland electoral roll. It is suggested that up to 15%-20% of people registered on the roll at any one time are dead or not resident at their enrolled address. As a result, person-years of observation in the inception cohort may be overestimated and the melanoma mortalities underestimated for both the control and screening groups. A telephone and postal survey of current address will be conducted among a sample of the inception cohort to estimate the size of this source of error.
All deaths from melanoma which occur among cases diagnosed within 15 years of the start of the intervention will be included in the analysis (fig 1) and will be identified by linkage to national and state mortality collections. The incidence of melanoma by tumour thickness will be documented.
The impact of the intervention on the diagnosis and treatment of skin lesions will be monitored at a geographical level through the Health Insurance Commission (the provider of universal health cover in Australia except within hospitals), and the impact on excisions of benign and malignant skin lesions will be monitored on an aggregated basis through all pathology laboratories servicing the study areas.
Behavioural outcome measures
The proportion of the adult population who have performed whole body skin self examination and the proportion who have had a whole body skin examination by a doctor during the intervention period will be measured in independent cross sectional community surveys by telephone interview in each of the intervention and control groups before and after intervention. The rate of uptake of screening will be monitored through postal cross sectional community surveys at 12 and 24 months.
Cost outcome measures
Financial costs associated with the screening programme will be recorded, including the costs of education, advertising, and recruitment; screening services; follow up of positive screens; participants' time and travel associated with the screening examination and follow up; and overall increases in procedures for the diagnosis and management of skin lesions.
Statistical analysis and study power
The principal analysis for the trial is the difference in mortalities from melanoma (deaths/person-years) between the intervention and control groups during the 15 years of follow up, 25 for cluster randomised designs in which the power of the analysis is improved by using mortalities for melanoma before the intervention to estimate variance between towns in mortality from melanoma. This will be an intention to treat analysis whereby deaths and person-years will be allocated to the intervention or control groups according to place of residence at the beginning of the intervention period. The intervention effect may be diluted to the extent that people in the inception cohort may move out of the intervention communities during the intervention period. Based on the 1996 Australian census, we estimate that about 4% of the inception cohort will be lost from the study area each year. This suggests that about 96% of the inception cohort will still be living in the study area after the 1st year of the intervention, 92% after 2 years, and 88% of the inception cohort will still be living in the study area at the end of the 3 year intervention. Thus, most of the sample will be exposed to the intense public education programme for most of the intervention period. With 15 years of follow up, the square of the coefficient of variation of cluster specific death rates (v) would be 0.25 as estimated from community specific death rates provided by the Queensland Cancer Registry, and with 25 years of historical data on mortalities from melanoma, the trial has 85% power (95% confidence interval (95% CI) 82% to 88%) to detect a 20% reduction in mortality from melanoma between intervention and control groups for a two sided test where α=0.05 (details of power calculations are available on request). A total of 317 deaths from melanoma are expected in the control group, and 249 deaths in the intervention group over the 15 year follow up period.
A simulation model developed by Knox 26 has been used widely to explore the benefits and cost effectiveness of screening programmes in Australia and internationally. 27 28 The Knox model was used here to estimate the expected change in mortality from melanoma as a result of the screening programme. Assuming reasonable values for sensitivity of screening of 95% and specificity of 60%, the model shows that 40% screening participation among those who would die from melanoma in the absence of the screening programme is consistent with a 22% reduction in mortality from melanoma. A conservative figure of 20% difference in mortality between screened and unscreened groups has been used in the power calculations. This seems a reasonable target in terms of the justification of any future population screening strategy.
The intervention
The intervention is an integrated, community based programme designed to promote two forms of skin screening: whole body skin self examination (defined as a careful examination of the skin on the whole body for early signs of skin cancer by the person themselves or another person who is not a doctor) and whole body clinical skin examination (defined as a visual examination by a doctor of the skin on the whole body, excluding areas covered by underwear). The goals of the intervention are that 60% of the inception cohort in the intervention group will receive at least one whole body screening examination by a doctor during the 3 year period, and 40% will receive at least two such examinations separated by at least a year, allowing an estimate of the expected rate of interval cancers with an annual screening regimen.
The intervention has three basic components. Firstly, a community education programme, targeted at adults 30 years and over, aims to raise awareness of skin cancer and the need for and acceptability of skin screening. Strategies include a guide for skin self examination delivered to all households, posters advertising the guide in community locations, brochures in doctors' surgeries, community talks, and advertisements and articles in local newspapers including endorsements by community leaders and local doctors. Secondly, an education programme for local general practitioners aims to improve their skills in early diagnosis and management of skin cancer and to encourage doctors to offer skin screening to their patients. Finally, to provide a high-profile focus for the programme and to assist local doctors to achieve the screening levels required, regular 2-6 week free skin cancer screening clinics are established, staffed by local doctors assisted as necessary by doctors hired from outside the community. Clinic patients with lesions requiring follow up are referred to and managed by their own doctor within routine clinical care.
Results of the first phase
At the time of writing, the first phase of the trial, involving nine pairs of communities (aggregate population 35 000 adults in nine intervention communities and 28 000 adults in nine control communities), has been underway for about 18 months. During this phase, all operational and monitoring procedures for the trial have been tested; the feasibility of implementing the intervention has been shown; and the cooperation and support of communities, medical practitioners, and pathology laboratories has been established (table 1). The feasibility of public skin screening clinics has been established and clinics have been fully operational in eight of the nine intervention towns. In the 1st year, an average of 51 patients were screened per doctor per day during a total 26 weeks of clinics.
The baseline cross sectional telephone survey and first annual postal survey of screening prevalence have been completed in all nine pairs of communities in this first phase. Response rates for the cross sectional telephone survey were 75% of 3054 eligible contacts for the screening group and 72% of 1158 eligible contacts for the control group. Response rates for the cross sectional postal survey were 70% and 74% for the screening and control groups respectively. In the three communities in which screening clinics were provided from the beginning of the intervention period, cross sectional surveys indicate a significant increase in screening participation after the first 12 months of the screening programme. In these communities, the reported prevalence of whole body examination from a doctor in the past year increased by a factor of 2.5 from 10.8% at baseline to 27.1% 12 months later, an absolute increase of 16.3 % (95% CI 12.1% to 20.5%)). There has been no significant increase in screening rates in matched control communities in the corresponding period (10.9% to 12.1%, an absolute increase of 1.2% (95% CI −3.3% to 5.7%)).
DISCUSSION
We have described a community based randomised trial of a population screening programme for melanoma. The design of the project has been successfully peer reviewed nationally and internationally, and the success of the first phase now underway in Queensland has shown the feasibility of the design and the intervention. The trial has had outstanding cooperation and interest from the communities and doctors involved and the level of participation in screening achieved to date is encouraging.
In Australia, most skin lesions are diagnosed and managed by general practitioners (GPs) rather than dermatologists and a general practice based programme is the only feasible option for a sustainable population skin screening programme. However, few studies have examined the performance characteristics of whole body skin examination by GPs and none in the primary care setting. In a recent Australian study in a hospital clinic, general practitioners achieved sensitivity of 95%-98% for detection of melanoma although specificity was lower (49%-52%). 29 This suggests that the sensitivity of visual examination by GPs for detecting melanoma is potentially as good as or better than that of other recommended cancer screening tests including mammography and faecal occult blood tests. An accurate estimation of sensitivity and specificity of skin screening by primary care physicians within the context of this screening programme will be available from this trial.
Australia has a highly aware population at high risk of melanoma. The greatest potential impact on earlier diagnosis of melanoma is likely to be through the combination of self screening and screening by a doctor, with both forms of skin examination operating in synergy, one (skin self examination with rapid presentation of suspicious lesions to a doctor) encouraging participation in the other (skin examination by doctors). The trial will assess the effectiveness of the screening programme as a whole in reducing mortality from melanoma. The separate effects of self screening and screening by a doctor may be important in other contexts, and information on this will be available from a case-control study of skin screening and its effect on the thickness of melanoma at diagnosis being conducted concurrently.
In conclusion, although it is sometimes assumed that a population based skin screening programme has the potential to lower mortality from melanoma, 30 31 there is little empirical evidence that this will in fact be the case. Screening is increasing in populations at high and moderate risk including Australia and the United States in the absence of conclusive scientific evidence of benefit and without full knowledge of the associated costs and hazards. The scientific evaluation of population screening for melanoma is an important issue for control of melanoma 32 and one which must be considered while controlled evaluations of screening are still possible.
